Key Insights

Highlights

Treatment Research

5 treatments under study, led by Paclitaxel

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00946712Phase 3Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Paclitaxel1
  • Cetuximab1
  • Bevacizumab1
  • Carboplatin1
  • Laboratory Biomarker Analysis1

Active Sponsors

  • SWOG Cancer Research Network1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Recurrent Large Cell Lung Carcinoma1
  • Recurrent Lung Adenocarcinoma1
  • Recurrent Squamous Cell Lung Carcinoma1
  • Stage Iv Squamous Cell Lung Carcinoma1
  • Stage Iv Lung Adenocarcinoma1

Activity Timeline